Search Page

1

Cite

Share

Mitochondrial D-loop "signatures" produced by low-stringency single specific primer PCR constitute a simple comparative human identity test.

Barreto G, Vago AR, Ginther C, Simpson AJ, Pena SD. Barreto G, et al. Among authors: ginther c. Am J Hum Genet. 1996 Mar;58(3):609-16. Am J Hum Genet. 1996. PMID: 8644720 Free PMC article.

Cite

Share

2

Cite

Share

DNA sequencing using a four-color confocal fluorescence capillary array scanner.

Kheterpal I, Scherer JR, Clark SM, Radhakrishnan A, Ju J, Ginther CL, Sensabaugh GF, Mathies RA. Kheterpal I, et al. Among authors: ginther cl. Electrophoresis. 1996 Dec;17(12):1852-9. doi: 10.1002/elps.1150171209. Electrophoresis. 1996. PMID: 9034766

Cite

Share

3

Cite

Share

Extent of heterogeneity in mitochondrial DNA of sub-Saharan African populations.

Melton T, Ginther C, Sensabaugh G, Soodyall H, Stoneking M. Melton T, et al. Among authors: ginther c. J Forensic Sci. 1997 Jul;42(4):582-92. J Forensic Sci. 1997. PMID: 9243823

Cite

Share

4

Cite

Share

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J. Eustace AJ, et al. Among authors: ginther c. BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1. BMC Cancer. 2018. PMID: 30305055 Free PMC article.

Cite

Share

5

Cite

Share

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL. Konecny GE, et al. Among authors: ginther c. J Natl Cancer Inst. 2014 Sep 30;106(10):dju249. doi: 10.1093/jnci/dju249. Print 2014 Oct. J Natl Cancer Inst. 2014. PMID: 25269487 Free PMC article.

Cite

Share

6

Cite

Share

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, Linnartz R, Zubel A, Slamon DJ, Finn RS. Hamidi H, et al. Among authors: ginther c. Br J Cancer. 2014 Oct 28;111(9):1788-801. doi: 10.1038/bjc.2014.475. Epub 2014 Aug 28. Br J Cancer. 2014. PMID: 25167228 Free PMC article.

Cite

Share

7

Cite

Share

POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D. Karlan BY, et al. Among authors: ginther cl. Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22. Gynecol Oncol. 2014. PMID: 24368280

Cite

Share

8

Cite

Share

AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.

Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS. Kalous O, et al. Among authors: ginther c. Breast Cancer Res Treat. 2013 Oct;141(3):397-408. doi: 10.1007/s10549-013-2702-z. Epub 2013 Oct 5. Breast Cancer Res Treat. 2013. PMID: 24091768

Cite

Share

9

Cite

Share

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.

Logan JE, Mostofizadeh N, Desai AJ, VON Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L, Chen HW, Ginther C, Taschereau E, Bui PH, Christensen JG, Belldegrun AS, Slamon DJ, Kabbinavar FF. Logan JE, et al. Among authors: ginther c. Anticancer Res. 2013 Aug;33(8):2997-3004. Anticancer Res. 2013. PMID: 23898052

Cite

Share

10

Cite

Share

Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.

Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE. Ihnen M, et al. Among authors: ginther c. Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. Epub 2013 May 31. Mol Cancer Ther. 2013. PMID: 23729402 Free PMC article.

Cite

Share